SCHEMBL3914712

SCHEMBL3914712

CCN(CC)CCNc1nc(-c2ccccc2O)nc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.62
KMT2A Q03164 10/20 0.62
RXFP1 Q9HBX9 1/20 0.62
POLB P06746 4/20 0.61
MAPT P10636 7/20 0.57
HIF1A Q16665 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
LMNA P02545 2/20 0.57
PTK2B Q14289 1/20 0.57
SLC2A1 P11166 1/20 0.56
FLT3 P36888 2/20 0.55
EGFR P00533 1/20 0.55
PKM P14618 1/20 0.55
GAA P10253 2/20 0.53
ALK Q9UM73 2/20 0.53
NTRK1 P04629 1/20 0.53
TLR9 Q9NR96 1/20 0.52
HCRTR1 O43613 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515707 0.88 TLR9 (0.67) MEN1KMT2ARXFP1POLBMAPT
SCHEMBL3907059 0.84 MEN1 (0.70) MEN1KMT2APOLBMAPTHIF1A
SCHEMBL1085522 0.84 POLB (0.83) MEN1KMT2APOLBSLC2A1FLT3
SCHEMBL4498282 0.83 MEN1 (0.68) MEN1KMT2ARXFP1POLBMAPT
SCHEMBL1083858 0.82 MEN1 (0.71) MEN1KMT2ARXFP1POLBMAPT
SCHEMBL3917004 0.81 MEN1 (0.70) MEN1KMT2ARXFP1POLBMAPT
SCHEMBL1083842 0.79 MEN1 (0.67) MEN1KMT2ARXFP1POLBMAPT
SCHEMBL4509057 0.79 CYP1A2 (0.79) MEN1KMT2ARXFP1POLBMAPT
SCHEMBL8907169 0.77 APP (0.62) POLBSLC2A1FLT3GAATLR9
SCHEMBL1084041 0.77 KMT2A (1.00) MEN1KMT2ARXFP1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US claimed
CN-101479246-A Amino-ethyl-amino-aryl (AEAA) compounds and their use CANCER REC TECH LTD (GB) 2009-07-08 CN claimed
EP-2024333-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-02-18 EP claimed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 WO claimed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 US disclosed
CN-101479246-A Amino-ethyl-amino-aryl (AEAA) compounds and their use CANCER REC TECH LTD (GB) 2009-07-08 CN disclosed
EP-2024333-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-02-18 EP disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 WO disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE PKD2, PKD1, AADAT MEN1 4237/4885KMT2A 230/4885RXFP1 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.